CC-92480 is a new drug being tested in a clinical trial for patients with
relapsed or resistant multiple myeloma (RRMM). This drug is a cereblon E3 ligase modulator that can change how certain proteins work in the body. It has shown to be very effective in reducing the amount of two proteins,
Ikaros and
Aiolos, which are important for the survival of
myeloma cells. CC-92480 binds to
cereblon with a much higher affinity than other drugs like
lenalidomide and
pomalidomide, leading to better destruction of Ikaros and Aiolos.
This drug also works well on many different types of myeloma cells, including those that have become resistant to other treatments. It can cause these cells to stop growing and to die, which is especially important for cells that are not affected by current treatments. In addition to this, CC-92480 can activate immune cells and increase the production of certain proteins that help the immune system fight
cancer.
The study found that CC-92480 is able to cause the death of myeloma cells in a way that depends on cereblon, and it can also help the immune system to kill these cells. The results of this study suggest that CC-92480 could be a promising new treatment for patients with RRMM.
Several authors of the study have affiliations with pharmaceutical companies, including
Celgene Corporation and Global Blood Therapeutics (GBT), where they hold positions such as employment and equity ownership.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
